BioSpace News Archive

Sensor-App-Phone Bundle Expected to Help Expedite Deployment of Remote Patient Management Solution to Patients Without Smartphones

Eve & Co Incorporated (the “Company” or “Eve & Co”) (TSX-V: EVE; OTCQX: EEVVF) is pleased to announce its financial results for the year ended December 31, 2019.

First Segment Debuts on Friday, April 17, 2020

Endo International plc (NASDAQ: ENDP) will announce its first–quarter 2020 financial results on May 7, 2020 and members of its senior management team will host a conference call and webcast at 8:00am ET before the U.S. financial markets open. The dial-in number to access the call is U.S./ Canada (866) 497-0462, International (67

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2020 financial results will be released on Thursday, April 30, after the market closes.

The U.S. Food and Drug Administration announced a further expansion of COVID-19 testing options through the recognition that spun synthetic swabs – with a design similar to Q-tips – could be used to test patients by collecting a sample from the front of the nose.

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today the closing of its public offering of 2,300,000 shares of its common stock,

CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2020 first quarter financial results will be released on Thursday, April 30, 2020 after the market closes.

Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the grant to 266 new employees of inducement stock options to purchase an aggregate of 33,040 shares of its common stock and restricted stock units for an aggregate of 267,729 shares of its common stock under its 2019 Inducement Award Plan. The stock opt

Tremendous commercialization has been prominently driving the growth of RNA based therapeutics and vaccines market worldwide. Persistence Market Research projects massive growth prospects for the global RNA based therapeutics and vaccines market over the seven-year period, 2019-2026.